Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study-Reference-Cited by-同舟云学术

Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study

Published:2019-09-23 Issue:1 Volume:27 Page:196-203
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Hartung H.‐P.¹^ORCID,Mallick R.²,Bril V.³⁴,Lewis R. A.⁵,Sobue G.⁶^ORCID,Lawo J.‐P.⁷,Mielke O.⁷,Durn B. L.²,Cornblath D. R.⁸,Merkies I. S. J.⁹¹⁰,van Schaik I. N.¹¹¹²,

Affiliation:

1. Department of Neurology UKD and Center for Neurology and Neuropsychiatry LVR Klinikum Medical Faculty Heinrich Heine University Düsseldorf Germany

2. CSL Behring LLC King of Prussia PA USA

3. Ellen and Martin Prosserman Centre for Neuromuscular Diseases Division of Neurology Department of Medicine University Health Network University of Toronto Toronto Canada

4. Institute for Research and Medical Consultations Imam Abdulrahman Bin Faisal University Dammam Saudi Arabia

5. Department of Neurology Cedars‐Sinai Medical Center Los Angeles CA USA

6. Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan

7. CSL Behring Marburg Germany

8. Department of Neurology Johns Hopkins University School of Medicine Baltimore MD USA

9. Department of Neurology Maastricht University Medical Center Maastricht The Netherlands

10. Department of Neurology St Elizabeth Hospital Willemstad Curacao

11. Department of Neurology Amsterdam University Medical Centres University of Amsterdam Amsterdam The Netherlands

12. Spaarne Gasthuis Haarlem The Netherlands

Funder

CSL Behring

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.14056

Reference17 articles.

1. Managing Multiple Chronic Conditions: A Strategic Framework for Improving Health Outcomes and Quality of Life

2. Quality of life in chronic disease patients

3. Chronic inflammatory demyelinating polyneuropathy: quality of life, sociodemographic profile and physical complaints

4. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study

5. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective;Journal of Clinical Medicine;2023-11-07

2. Pain-resolving immune mechanisms in neuropathic pain;Nature Reviews Neurology;2023-03-01

3. A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States;PharmacoEconomics - Open;2023-02-09

4. Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review;Value in Health;2023-01

5. Immunoglobulin Use for the Management of Painful Peripheral Neuropathy: A Systematic Review and Meta-Analysis;Pain and Therapy;2022-08-04